Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Receives Average Rating of "Moderate Buy" from Brokerages

Key Points

• "Moderate Buy" consensus from 10 brokerages (9 buys, 1 sell) with a 12‑month average price target of $41.56, and multiple major houses (BofA, UBS, JPMorgan, Truist, Scotiabank) recently raising ratings/targets.
• Q1 earnings beat — Teva reported $0.53 EPS and $3.98B revenue, driven by branded products (Austedo, Ajovy, Uzedy), supporting near‑term earnings growth and a sell‑side FY EPS consensus of ~2.6.
• Strategic shift toward higher‑margin branded growth highlighted by the ~$900M acquisition of Emalex (ecopipam) and large institutional inflows (notably Norges Bank and other major funds), signaling investor confidence in a re‑rating.

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) has been assigned an average rating of "Moderate Buy" from the ten research firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $41.5556.

A number of brokerages have weighed in on TEVA. Bank of America raised their price objective on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a "buy" rating in a research note on Thursday, April 9th. Scotiabank raised their price objective on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a "sector outperform" rating in a research note on Thursday, January 29th. Truist Financial raised their price objective on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a "buy" rating in a research note on Thursday. JPMorgan Chase & Co. raised their price objective on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an "overweight" rating in a research note on Thursday. Finally, UBS Group raised their price objective on Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a "buy" rating in a research note on Thursday.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE TEVA opened at $35.00 on Friday. Teva Pharmaceutical Industries has a fifty-two week low of $14.99 and a fifty-two week high of $37.35. The business has a 50 day moving average price of $31.15 and a two-hundred day moving average price of $29.39. The company has a quick ratio of 0.80, a current ratio of 1.01 and a debt-to-equity ratio of 1.70. The firm has a market cap of $40.24 billion, a PE ratio of 26.31, a price-to-earnings-growth ratio of 3.08 and a beta of 0.86.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings data on Tuesday, March 31st. The company reported $0.53 earnings per share for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%.The firm had revenue of $3.98 billion during the quarter. Sell-side analysts expect that Teva Pharmaceutical Industries will post 2.6 earnings per share for the current fiscal year.

More Teva Pharmaceutical Industries News

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Q1 earnings beat and revenue upside driven by branded products (Austedo, Ajovy, Uzedy), which lifted investor sentiment and underpins near‑term earnings growth. Read More.
• Positive Sentiment: Multiple broker upgrades and higher price targets — UBS, Truist, JPMorgan and Piper Sandler raised targets/ratings over the last day, signaling analyst confidence in a re‑rating and further upside for the stock. Read More. Read More.
• Positive Sentiment: Teva agreed to acquire Emalex for ~\$900M to add ecopipam (paediatric Tourette’s) — a late‑stage, de‑risked asset that bolsters the specialty/innovative portfolio and supports the narrative that Teva is shifting toward higher‑margin branded growth. Read More.
• Neutral Sentiment: Teva published its 2025 Healthy Future Report and says it met all sustainability‑linked bond targets — positive for ESG profile and potentially credit metrics, but unlikely to move near‑term revenues. Read More.
• Neutral Sentiment: Blackstone put significant financing behind Teva in a recent deal — signals institutional interest/validation but primarily affects capital structure and optionality rather than immediate EPS. Read More.
• Neutral Sentiment: Industry reports list Teva among leaders in oral solid dosage contract manufacturing — positive for long‑term service demand exposure but not an immediate earnings catalyst. Read More.
• Negative Sentiment: Generics revenue remains weak even as branded sales grow — raises questions about sustainability of overall top‑line growth if branded momentum slows. Read More.
• Negative Sentiment: After a rapid share run‑up, some analysts and coverage pieces note valuation/volatility risk — investors should weigh near‑term upside from upgrades against stretched multiples and execution risk. Read More.

Insider Buying and Selling

In other news, insider Placid Jover sold 14,150 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $31.67, for a total value of $448,130.50. Following the completion of the transaction, the insider owned 6,774 shares in the company, valued at approximately $214,532.58. This trade represents a 67.63% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Richard Daniell sold 17,295 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $31.67, for a total value of $547,732.65. Following the completion of the transaction, the executive vice president owned 85,755 shares of the company's stock, valued at approximately $2,715,860.85. The trade was a 16.78% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 920,901 shares of company stock worth $30,056,789. 0.54% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in TEVA. Norges Bank acquired a new position in shares of Teva Pharmaceutical Industries in the 4th quarter worth approximately $1,098,060,000. Harel Insurance Investments & Financial Services Ltd. grew its position in shares of Teva Pharmaceutical Industries by 19.2% in the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 44,951,773 shares of the company's stock worth $1,402,945,000 after acquiring an additional 7,255,083 shares in the last quarter. Wellington Management Group LLP grew its position in shares of Teva Pharmaceutical Industries by 39,228.4% in the 3rd quarter. Wellington Management Group LLP now owns 6,895,838 shares of the company's stock worth $139,296,000 after acquiring an additional 6,878,304 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd grew its position in shares of Teva Pharmaceutical Industries by 18.8% in the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 37,404,106 shares of the company's stock worth $1,171,378,000 after acquiring an additional 5,917,423 shares in the last quarter. Finally, Schroder Investment Management Group grew its position in shares of Teva Pharmaceutical Industries by 261.1% in the 4th quarter. Schroder Investment Management Group now owns 7,426,885 shares of the company's stock worth $231,793,000 after acquiring an additional 5,370,253 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company's stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. NYSE: TEVA is an Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines. The company's core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva's product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.